What is the appropriate stereotactic body radiation therapy (SBRT) dose for a solitary mediastinal lymph node measuring 1.2 cm?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

SBRT Dose for Solitary Mediastinal Lymph Node (1.2 cm)

For a 1.2 cm solitary mediastinal lymph node, I recommend 35 Gy in 5 fractions (7 Gy per fraction), which represents the most commonly used and well-validated SBRT regimen for oligometastatic mediastinal lymph nodes with excellent local control and acceptable toxicity.

Rationale and Evidence Base

The 2026 ASTRO dose-volume histogram consensus guidelines 1 provide critical organ-at-risk constraints for ultrahypofractionated 5-fraction lung SBRT regimens (10-12 Gy per fraction to 50-60 Gy total). While these guidelines focus on primary lung cancer, they establish the safety framework for mediastinal SBRT delivery.

The most robust clinical evidence comes from recent multi-institutional studies specifically addressing mediastinal lymph node oligometastases:

  • A 2025 multicentre retrospective study 2 of 63 mediastinal lymph node metastases treated with SBRT reported median dose of 30 Gy in 5 fractions, achieving 1-year and 2-year local control rates of 96.9% and 91.8% respectively, with only one late grade 3 toxicity.

  • A 2023 single-center CyberKnife series 3 demonstrated that 36 Gy in 6 fractions (66% of their cohort) had significantly lower local progression rates compared to other fractionation schemes, with 6,12, and 18-month local control of 94%, 88%, and 72%.

  • A 2021 large academic center series 4 of 84 mediastinal/hilar metastases used median dose of 35 Gy in 5 fractions (range 30-50 Gy), achieving 2-year local failure rate of only 9.0%, though with 11.5% grade ≥3 toxicity (mostly transient).

Dose Selection Algorithm

For your 1.2 cm mediastinal lymph node, consider this approach:

  1. Standard recommendation: 35 Gy in 5 fractions (BED10 = 59.5 Gy)

    • Most commonly reported in literature 4, 5
    • Balances efficacy with toxicity
    • Achieves >90% local control at 2 years
  2. Alternative if proximity to critical structures: 36 Gy in 6 fractions (6 Gy per fraction)

    • Superior local control demonstrated 3
    • Lower dose per fraction may reduce toxicity risk
    • BED10 = 61.2 Gy (similar biological effect)
  3. Dose escalation consideration: 40-50 Gy in 5 fractions

    • Reserved for larger nodes or when maximum local control is paramount
    • Must ensure all OAR constraints are met 1
    • Higher toxicity risk (11.5% grade ≥3) 4

Critical Organ-at-Risk Constraints (5-Fraction Regimen)

When planning 35 Gy in 5 fractions, you must respect these constraints 1:

  • Esophagus: D0.035cc ≤38 Gy (primary goal); D5cc ≤19.5 Gy
  • Heart: D0.035cc ≤38 Gy; D15cc ≤32 Gy
  • Trachea/Main Bronchus: D0.035cc ≤40 Gy; D0.5cc ≤21 Gy
  • Spinal Canal: D0.035cc ≤32 Gy (for 5-fraction regimen)
  • Great Vessels: D0.035cc ≤105% of prescription dose
  • Brachial Plexus: D0.035cc ≤32 Gy

Technical Planning Considerations

Modern techniques are mandatory 6, 2:

  • Use IMRT or VMAT (not conventional 3D-conformal)
  • Define GTV based on PET-CT imaging (gold standard for nodal metastases) 7
  • CTV = GTV + 0.5-1.0 cm margin (respecting anatomic boundaries) 6
  • PTV accounts for setup uncertainty and motion
  • Consider 4D-CT for motion assessment 8

Common pitfall: The mediastinum contains multiple dose-limiting serial organs. If you cannot meet all OAR constraints with 35 Gy in 5 fractions, do not compromise the constraints—instead, either:

  1. Switch to 36 Gy in 6 fractions (lower dose per fraction)
  2. Consider moderately hypofractionated regimen (e.g., 45-50 Gy in 10 fractions)
  3. Use conventional fractionation if SBRT is not feasible

Expected Outcomes

With appropriate dosing (30-36 Gy in 5-6 fractions):

  • Local control: 88-97% at 1-2 years 2, 3, 4
  • Median time to new systemic therapy: 12-17 months 2, 3
  • Grade ≥3 toxicity: 0-11.5% (mostly transient) 2, 3, 4
  • Overall survival: 75-86% at 2 years 2, 4

The evidence strongly supports that SBRT for oligometastatic mediastinal lymph nodes delays systemic therapy progression and provides excellent local control with acceptable toxicity when delivered with appropriate dose constraints.

Related Questions

A 15‑month‑old child has a 2‑day history of rare, brief, middle‑pitched inspiratory noises lasting 2–3 breaths, not related to position, activity, or time of day, with mild nasal congestion but otherwise normal feeding, hydration, elimination, development, and immunizations. What is the appropriate management?
What is the recommended evaluation and management for a 19-year-old female with sudden hair loss over the past 5 days?
Should a postero‑anterior and lateral chest radiograph be obtained for a 10 mm nodular opacity in the left upper lung to differentiate a solitary nodule from a confluence of shadows?
Is a blood pressure of 146/84 mm Hg an indication to start antihypertensive medication?
How many ampoules of a 17.7% sodium solution are needed to prepare a 3% hypertonic sodium solution?
In a patient who experienced several hours of palpitations, now in sinus rhythm with an elevated troponin (~900 ng/L), why does a troponin decrease greater than 20 % indicate a non‑ST‑segment elevation myocardial infarction (NSTEMI) rather than a resolved tachyarrhythmia?
How should constipation be managed in a patient with a negative abdominal X‑ray (KUB) who is not responding to polyethylene glycol (PEG 3350) and may require a Fleet (sodium phosphate) enema or a switch to Dulcolax (bisacodyl)?
In a patient with resolved palpitations and sinus rhythm, does a second troponin of 908 ng/L measured six hours after the initial ≈900 ng/L value indicate an acute type 1 NSTEMI or a type 2 supply‑demand myocardial injury?
What temperature range defines hypothermia in a newborn infant?
How should hyponatremia be managed in an elderly patient with chronic kidney disease?
What is terazosin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.